TL;DR
In this Turkish single-center cohort treated during the early TAVI era, long-term outcomes reflected the advanced age and comorbidity burden of the study population and should be interpreted in the context of substantial competing mortality.
BACKGROUND Bioprosthetic valve failure (BVF) is a key clinical endpoint for evaluating valve durability after transcatheter aortic valve implantation (TAVI). However, in populations with substantial competing mortality or heterogeneous follow-up durations, the estimated incidence of BVF may vary according to evaluation...
BACKGROUND Data on early outcomes of the novel balloon-expandable (BE) Octapro transcatheter heart valve (THV) in real-world practice are limited. We sought to assess procedural safety and early outcomes of the Octapro in patients with severe native aortic stenosis (AS) undergoing transcatheter aortic valve implantatio...
In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.
Introduction Transcatheter heart valve implantation into a failed surgical heart valve (THV-in-SHV) is an established reintervention strategy for degenerated aortic bioprostheses; however, early procedural outcomes, discharge hemodynamics, and standardized safety remain clinically relevant in routine practice. Material...
Among patients treated with newer-generation transcatheter valves, SEV demonstrated more favorable hemodynamic performance compared with BEV, however, short- and mid-term mortality rates remained similar between the two groups.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
